Patents by Inventor Scott D. Putney

Scott D. Putney has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 5262301
    Abstract: Novel recombinant HTLV-III fusion proteins denoted R10, RB1, 590 and the HIV portion of each of these proteins are useful in the diagnosis, prophylaxis or therapy of AIDS. Protein R10 is a 95 kD fusion protein; protein PB1 is a 26 kD fusion protein and protein 590 is an 86 kD fusion protein.
    Type: Grant
    Filed: January 3, 1992
    Date of Patent: November 16, 1993
    Assignee: Repligen Corporation
    Inventors: Scott D. Putney, Debra Lynn, Kashayar Javaherian, William T. Mueller, John Farley
  • Patent number: 5142025
    Abstract: Novel recombinant HTLV-III fusion proteins denoted R10, PB1, 590, KH1, and the HIV portion of each of these proteins are useful in the diagnosis, prophylaxis or therapy of AIDS. Protein R10 is a 95 kD fusion protein; protein PB1 is a 26 kD fusion protein; protein 590 is an 86 kD fusion protein; and protein KH1 is a 70 kD fusion protein. These proteins are considered to be especially useful to prepare vaccines for the HTLV-III virus.
    Type: Grant
    Filed: September 24, 1990
    Date of Patent: August 25, 1992
    Assignee: Repligen Corporation
    Inventors: Scott D. Putney, Debra Lynn, Kashayar Javaherian, William T. Mueller, John Farley
  • Patent number: 4521509
    Abstract: 2'-deoxyadenosine 5'-0-(1-thiotriphosphate) (dATP(.alpha.-S)) was introduced into the 3'-ends of DNA restriction fragments with E. coli DNA polymerase I to give phosphorothioate internucleotide linkages. Such "capped " 3'-ends were found to be resistant to exonuclease III digestion. Moreover, the resistance to digestion is great enough that, under the conditions employed, just one strand of a double helix was digested by exonuclease III when "cap" was placed at only one end; when digestion was carried to completion, the production of intact single strands resulted. When digestion with exonuclease III was limited, and followed by S1 nuclease treatment, double stranded DNA fragments asymmetrically shortened from just one side were produced. In this way thousands of nucleotides can be selectively removed from one end of a restriction fragment.
    Type: Grant
    Filed: November 24, 1982
    Date of Patent: June 4, 1985
    Assignee: Research Corporation
    Inventors: Stephen J. Benkovic, Scott D. Putney, Paul R. Schimmel